Cancer-Specific Antihuman Podoplanin Antibody chLpMab-2f Exerts Antitumor Effects Against Pleural Mesothelioma

Our plain-English summary of Cancer-Specific Antihuman Podoplanin Antibody chLpMab-2f Exerts Antitumor Effects Against Pleural Mesothelioma, by A. Yoshida, S. Abe, T. Izumi, et al (Cancer Science, 2026).

The study

• Authors: A. Yoshida, S. Abe, T. Izumi, S. Itakura, K. Yamada, T. Wada, T. Yamamoto, C. Sato, A. Mitsuhashi, H. Ogino, S. Sato, T. Shinohara, M. Hanibuchi, M.K. Kaneko, Y. Kato, Y. Nishioka
• Journal: Cancer Science
• Published: 2026;117(4):917-928
• Read it: PubMed · Publisher · Free full text

Abstract

Pleural mesothelioma (PM) is a malignancy with a poor prognosis owing to its resistance to chemotherapy. To develop a novel treatment for PM, podoplanin (PDPN), a transmembrane glycoprotein, has attracted significant attention because it is highly expressed in PM and is used for its diagnosis. We previously reported that NZ-12, a human chimeric antihuman PDPN antibody, exhibits antitumor effects against human PM cells through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Additionally, we developed a cancer-specific monoclonal antibody (CasMab) production technology and produced a mouse-human chimeric cancer-specific antihuman PDPN antibody, chLpMab-2, along with an afucosylated version, chLpMab-2f, to enhance ADCC activity. This study aimed to evaluate whether chLpMab-2f exhibits specific antitumor effects against PM in a preclinical model. We demonstrated that chLpMab-2f recognized the surface PDPN of human PM cell lines and human PM patient tissue but did not react with human normal tissues such as lung and kidney tissues. Furthermore, these antibodies exhibited ADCC and CDC activity against PDPN-positive PM cells while showing reduced toxicity toward non-malignant kidney-derived PDPN-positive cells, such as HEK-293FT. Additionally, chLpMab-2f demonstrated stronger ADCC activity through more efficient NK cell activation in comparison to chLpMab-2. Moreover, chLpMab-2f suppressed tumor progression in subcutaneously and intrathoracically transplanted human PM cells in mice. These findings suggest that PDPN-targeting immunotherapy with chLpMab-2f generated by CasMab technology could provide an effective treatment for PM with decreased toxicity toward normal tissues.

© 2026 The Author(s). Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

In plain English

This laboratory and animal study tested chLpMab-2f, an experimental antibody designed to attach to a protein called podoplanin (PDPN) in a form found on cancer cells, as a possible treatment for pleural mesothelioma. It did not study asbestos exposure. The authors used human pleural mesothelioma cell lines, purchased tissue samples, immune cells from healthy blood donors, and mice carrying human mesothelioma cells under the skin or in the chest cavity. The mice were treated with the antibody plus human natural killer (NK) cells. chLpMab-2f stained mesothelioma tissue but not kidney or lung tissue at the same concentration. It killed mesothelioma cells through NK cells more strongly than an earlier version, chLpMab-2. It was much less damaging to non-cancer kidney-derived HEK-293FT cells than a non-cancer-specific antibody, NZ-12f. The authors reported that it inhibited tumor progression in mice, but the available text gives no numbers. The authors noted that toxicity to normal human tissues was not assessed and that the effects depended on giving human NK cells. They concluded that chLpMab-2f may be a novel therapeutic agent for pleural mesothelioma.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Laboratory (in vitro) study and animal experiment in mice testing an experimental antibody
• Who was studied: Human pleural mesothelioma cell lines (ACC-MESO-1, ACC-MESO-4, NCI-H290, Y-MESO-12, and also NCI-H226 and MSTO-211H), the non-malignant kidney-derived HEK-293FT cell line, purchased human PM, lung and kidney tissue (the PM tissue was desmoplastic, a variant of sarcomatoid PM), blood cells from healthy donors, and male SCID mice in Japan. Numbers of mice per group are not given in the available text.
• Exposure: No asbestos exposure was studied. The intervention was the antibody chLpMab-2f (350 μg per mouse, injected into the abdominal cavity twice a week) or control human IgG, given with human NK cells once a week. Mice received ACC-MESO-4 cells under the skin or NCI-H290 cells into the chest cavity.
• Main results:
  • In tissue staining, chLpMab-2f reacted with human PM tissue but did not recognize human kidney and lung tissue at the same antibody concentration.
  • chLpMab-2f showed stronger NK-cell-mediated killing (ADCC) than chLpMab-2, through more efficient NK cell activation.
  • chLpMab-2 and chLpMab-2f bound the complement component C1q almost equally.
  • chLpMab-2f caused much lower complement-dependent killing (CDC) of non-malignant HEK-293FT cells than NZ-12f, a non-cancer-specific antibody.
  • chLpMab-2f inhibited tumor progression in mice. No numbers for tumor size, weight or pleural effusion survive in the available text.
• The authors' conclusion: The authors concluded that chLpMab-2f showed antitumor effects against PM in laboratory tests and in mice, and suggested it may be a novel therapeutic agent for PM.
• Limitations the authors state:
  • The toxicity of chLpMab-2f to PDPN-positive normal tissues, including lung and kidney, was not assessed. It could not be evaluated in the mouse model because PDPN differs between humans and mice.
  • The antitumor effects in mice depended on giving human NK cells.

Topics

The National Library of Medicine indexes this study under subjects our site covers: Lung cancer, Mesothelioma.

Medical terms in this study, explained in our Lexicon: Podoplanin (D2-40), Pleural Mesothelioma, Prognosis, Chemotherapy, Glycoprotein, Monoclonal Antibody, Immunotherapy.

Related studies

• Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity — M.K. Kaneko, S. Yamada, et al. (2017)
• Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model — S. Abe, M.K. Kaneko, et al. (2016)
• Therapeutic efficacy evaluation of radioimmunotherapy with 90 Y-labeled anti-podoplanin antibody NZ-12 for mesothelioma — H. Sudo, A.B. Tsuji, et al. (2019)
• Establishment of Mouse Monoclonal Antibody LpMab-13 Against Human Podoplanin — S. Ogasawara, M.K. Kaneko, et al. (2016)
• Antipodoplanin antibody enhances the antitumor effects of CTLA-4 blockade against malignant mesothelioma by natural killer cells — H. Yoneda, A. Mitsuhashi, et al. (2024)
• Epitope Mapping of Monoclonal Antibody PMab-233 Against Tasmanian Devil Podoplanin — M. Sano, M.K. Kaneko, et al. (2019)

Browse more research in Cancer Science, or return to medical research.